PE20020505A1 - Grupos quinuclidina sustituidos con heteroarilo para el tratamiento de enfermedades - Google Patents

Grupos quinuclidina sustituidos con heteroarilo para el tratamiento de enfermedades

Info

Publication number
PE20020505A1
PE20020505A1 PE2001000834A PE2001000834A PE20020505A1 PE 20020505 A1 PE20020505 A1 PE 20020505A1 PE 2001000834 A PE2001000834 A PE 2001000834A PE 2001000834 A PE2001000834 A PE 2001000834A PE 20020505 A1 PE20020505 A1 PE 20020505A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
rent
carboxamide
oct
alkyl
Prior art date
Application number
PE2001000834A
Other languages
English (en)
Inventor
Jason K Myers
Bruce N Rogers
Groppi
David W Piotrowski
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20020505A1 publication Critical patent/PE20020505A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 ES H, ALQUILO, CICLOALQUILO, ALQUILO HALOGENADO, ARILO; R2 ES H, ALQUILO, ALQUILO HALOGENADO, ALQUILO SUSTITUIDO, CICLOALQUILO, BENCILO, ENTRE OTROS; W ES EL GRUPO a ENTRE OTROS DONDE V E Y SON =N, =C(R5)-; Z ES =N, =CH- Y CON LA CONDICION DE QUE CUANDO V E Y SEAN AMBOS =C(R5)- Y Z ES =CH, SOLAMENTE UN =C(R5)- PUEDE SER =CH- Y CON LA CONDICION ADICIONAL DE QUE CUANDO U ES O, Y ES =C(R5)- Y Z ES =C(R5)-, V NO PUEDE SER =N-; R3 ES H, ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ALQUILO HALOGENADO, CICLOALQUILO HALOGENADO, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N[(3R)-1-AZABICICLO[2.2.2]OCT-3-IL]-5-FENIL-TIOFEN-2-CARBOXAMIDA, N[(3R)-1-AZABICICLO[2.2.2]OCT-3-IL]-5-(4-CLOROFENIL)-TIOFEN-2-CARBOXAMIDA, N[(3R)-1-AZABICICLO[2.2.2]OCT-3-IL]-5-(3-CLOROFENIL)-TIOFEN-2-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS ACTUAN SOBRE LOS RECEPTORES DE LA ACETILCOLINA O7 NICOTINICOS Y REGULA LA ACTIVIDAD DEL SISTEMA NERVIOSO CENTRAL
PE2001000834A 2000-08-21 2001-08-21 Grupos quinuclidina sustituidos con heteroarilo para el tratamiento de enfermedades PE20020505A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22665200P 2000-08-21 2000-08-21
US28483201P 2001-04-19 2001-04-19

Publications (1)

Publication Number Publication Date
PE20020505A1 true PE20020505A1 (es) 2002-06-12

Family

ID=26920741

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000834A PE20020505A1 (es) 2000-08-21 2001-08-21 Grupos quinuclidina sustituidos con heteroarilo para el tratamiento de enfermedades

Country Status (5)

Country Link
EP (1) EP1311505A2 (es)
JP (1) JP2004506734A (es)
AU (1) AU2001282910A1 (es)
PE (1) PE20020505A1 (es)
WO (1) WO2002016355A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003283648A1 (en) * 2002-12-06 2004-06-30 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
EP1587511A2 (en) * 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Treatment of diseases with alpha-7 nach receptor full agonists
AU2004282201A1 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
SE0303076D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
SE0303075D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 4-substituted imidazoles
BRPI0417933A (pt) * 2003-12-22 2007-04-17 Astrazeneca Ab composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
KR20060125812A (ko) * 2003-12-22 2006-12-06 아스트라제네카 아베 니코틴성 아세틸콜린 수용체 리간드
JP2007538046A (ja) 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ 新規なアザビシクロアリール誘導体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
MX2010002258A (es) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Compuestos terapeuticos de isoxazol.
CA2701126A1 (en) 2007-10-01 2009-04-09 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, and pharmaceutical uses thereof
WO2009098282A1 (en) * 2008-02-06 2009-08-13 Novasaid Ab Low molecular weight 2,5-disubstituted thiophene derivatives and use thereof in therapy
RS52941B (en) 2008-02-13 2014-02-28 Targacept Inc. A COMBINATION OF ALFA 7 NICOTINE AGONISTS AND ANTIPSYCHOTICS
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EA024170B1 (ru) * 2011-02-23 2016-08-31 Люпин Лимитед ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ nAChR АЛЬФА7
WO2013005153A1 (en) * 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Tlr阻害作用を有するチオフェン誘導体
JPWO2014069554A1 (ja) * 2012-10-31 2016-09-08 東レ株式会社 キヌクリジンアミド誘導体及びその医薬用途
EP3166940A4 (en) 2014-07-11 2018-04-25 Alpharmagen, LLC Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
IT1228288B (it) * 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EP0984970B1 (en) * 1997-05-30 2003-11-19 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
SE9904176D0 (sv) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
JP2004506734A (ja) 2004-03-04
AU2001282910A1 (en) 2002-03-04
EP1311505A2 (en) 2003-05-21
WO2002016355A2 (en) 2002-02-28
WO2002016355A3 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
PE20020505A1 (es) Grupos quinuclidina sustituidos con heteroarilo para el tratamiento de enfermedades
ES2185999T3 (es) Derivados de quinazolina y composiciones farmaceuticas que los contienen.
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
NL980008I1 (nl) Gebruik van sertindool voor de behandeling van schizofrenie.
ES2139638T3 (es) 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.
AR012264A1 (es) Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
CO4900033A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas que los contienen .
DE59712501D1 (de) 1-benzyl-3-(substituiertes-hetaryl)-kondensierten pyrazol-derivaten zur behandlung von erkrankungen des herz-kreislaufsystems und des zentralnervensystems
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ES2084361T3 (es) Derivados de quinuclidina.
DK0937041T3 (da) Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
GR3019450T3 (en) Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
CO4900035A1 (es) Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
MXPA05010621A (es) Pirimidinonas sustituidas.
PE20001037A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
ES2160648T3 (es) Derivados de piridina.
ES2164889T3 (es) Semicarbazonas con actividad sobre el snc y preparados farmaceuticos a base de las mismas.
AR028705A1 (es) Bis-arilsulfonas
EE03215B1 (et) 3-kinoloonkarboksüülhappe derivaatide ühereaktoriline saamismeetod

Legal Events

Date Code Title Description
FA Abandonment or withdrawal